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Objectives: Binge Eating Disorder (BED) recently moved, with slight modifica-
tion, from the DSM-IV appendix to a fully recognized disorder in DSM-5. There 
is limited information on the impact of BED on productivity and social function-
ing. One cross-national epidemiological study reported BED was associated with 
an increased number of days of role impairment. We report here the associations 
of DSM-5 defined BED, with work productivity and functional impairment in the 
work/school, social and family life domains. MethOds: An Internet survey of a 
representative sample of US adults, conducted in fall, 2013, included questions 
related to demographics, general health, psychiatric comorbidities, assessment for 
DSM-5 criteria for BED, the Work Productivity and Activity Impairment questionnaire 
(WPAI) and the Sheehan Disability Scale (SDS). SDS and WPAI were compared (BED 
vs no BED groups) via ANOVA. Results: Among 22,397 respondents, 344 (1.5%) 
participants (242 women and 102 men) met full DSM-5 criteria for BED, 1,616 (7.2%) 
reported overeating with loss of control but not meeting DSM-V criteria for BED. 
The remainder of the respondents, 20,437 (91.3%), may have reported overeating but 
no other BED symptoms. Relative to those with no BED, those with BED had higher 
mean[SD] impairment on SDS work/school (3.86[3.62]) vs 1.01[2.21], p< 0.001), social 
life (5.29[3.49] vs 1.22[2.33], p< 0.001) and home/family life (4.89[3.44] vs 1.18[2.26], 
p< 0.001). As measured by WPAI, those with BED, compared to those in the no BED 
group, had higher mean[SD] scores for absenteeism (9.59[19.97] vs 2.90[12.95]), 
presenteeism (30.00[31.64] vs 10.86[20.07]), work productivity loss (33.19[33.85] vs 
12.60[23.22]), and activity impairment (43.52[34.36] vs 19.94[27.22]) respectively 
(p< 0.001 for all). cOnclusiOns: This is the first large population study to examine 
the association of BED, using DSM-5 criteria, with work productivity and daily func-
tioning. Results suggest that those with BED experience considerable impairment 
in functioning and work productivity relative to those without BED.
PMH70
Do DePresseD Patients on aDjunctive atyPical antiPsycHotics 
DeMonstrate a better quality of life coMPareD to tHose on 
antiDePressants only? (a coMParative cross-sectional stuDy of a 
nationally rePresentative saMPle of tHe uniteD states PoPulation)
Alruthia Y.S., Hong S.H., Solomon D.K.
The University of Tennessee Health Science Center, Memphis, TN, USA
Objectives: The adjunctive use of some atypical antipsychotics (AAPs) has shown 
to provide some benefits in improving the depressive symptoms in patients with 
treatment-resistant depression. However, little is known about the impact of these 
agents on patients’ health-related quality of life (HRQoL). MethOds: Patients 
with self-reported depression (ICD-9: 296, 300, and 311), and have used the given 
AAPs and/or antidepressants for at least a year, were identified in the Medical 
Expenditure Panel Survey (MEPS) of 2008-2011. The patients were classified into 
users of adjunctive AAPs (i.e., antidepressants plus AAPs) and users of antidepres-
sants only. The AAPs were identified based on documented evidence, and included 
risperidone, aripiprazole, quetiapine, olanzapine, and ziprasidone. Multivariate 
linear regression analyses were conducted to determine whether the utilization 
of AAPs was associated with the Physical Component Summary-12 (PCS12) or with 
Mental Component Summary-12 (MCS-12) of HRQoL measure. Socio-demographics, 
Charlson Comorbidity Index, psychotherapy (i.e., cognitive behavioral therapy), 
Patient Health Questionniare-2 (PHQ-2) scores, and the number of prescription 
medications associated with depression were controlled. Results: A total of 3,638 
participants reported to have depression and to have used the given AAPs and/or 
antidepressants for at least a year during the period of 2008-2011 (306 on AAPs vs. 
3,332 on antidepressants only). The study subjects were ≥ 18 years, predominately 
White (91.9%) and female (71%). The adjunctive AAPs utilization was not associated 
with higher scores in the PCS-12 (β = 1.455, 95% CI = − 0.1366-3.0459, p = 0.0729). 
Rather, it was negatively associated with the MCS-12 scores (β = − 1.549, 95% CI 
= − 3.0171-− 0.0822, p = 0.0386). cOnclusiOns: The adjunctive utilization of AAPs 
was not associated with higher scores of HRQoL. Future studies should examine 
whether poor mental scores of HRQoL have occurred from lower medication adher-
ence to AAPs or from lower baseline HRQoL scores among users of adjunctive AAPs.
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Objectives: People with dementia are sensitive to cognitive side effects of 
anticholinergic drugs and this may adversely affect their Health Related Quality of 
Life (HRQoL). The study examined the association between the use of drugs with 
anticholinergic properties and HRQoL among community-dwelling elderly dementia 
patients. MethOds: This was a retrospective longitudinal cohort study involving 
elderly (age> = 65 years) patients with a diagnosis of dementia, using data from 
Medical Expenditure Panel Survey (MEPS) panels 9 to 13. Each panel consisted of 
five rounds which spanned over the period of two years. Patients who used anticho-
linergic drugs in round 1 or 2 were excluded. Anticholinergic drug exposure was 
measured in rounds 3 and 4 using Anticholinergic Drug Scale (ADS), an ordinal scale 
that rates anticholinergic drugs into levels 0 - 3 in increasing order of anticholinergic 
potency. The outcomes of interest were Physical Component Score (PCS) and Mental 
Component Score (MCS) based on Short-Form 12 (SF-12) health survey, measured 
in round 4. Two separate multiple linear regressions analyses were performed to 
determine the association of anticholinergic drugs with PCS and MCS while adjust-
ing for sociodemographic variables and baseline HRQoL measures. Results: The 
study included 112 patients, of which, 15.18% used anticholinergic drugs. Majority 
of the study participants were between ages of 65-79 (53%), females (57%), and with 
poor or low family income (65%). After controlling for sociodemographic and base-
line characteristics, anticholinergic drug use was significantly associated with 5.75 
units reduction in PCS (p-value: 0.01) whereas no association was found between 
anticholinergic use and MCS. Baseline HRQoL measures were found significant in 
both models. cOnclusiOns: Anticholinergic medications were associated with 
item Medical Outcomes Study Short-Form Health Survey version 2 (SF-12v2) among 
adults with autism. MethOds: Study data was collected using an online survey 
(Qualtrics software system) of 291 adults with autism registered with the Interactive 
Autism Network (IAN). Using confirmatory factor analysis, construct validity of the 
SF-12v2 was examined by comparing model fits across four different iterations of 
the SF-12v2 two-factor structure. Known-groups validity was assessed by compar-
ing SF-12v2 physical component summary (PCS) and mental component summary 
(MCS) score by autism severity. Internal consistency reliability was determined using 
Cronbach’s alpha. Floor and ceiling effects were assessed based on the percentage of 
participants scoring the lowest and highest possible score, respectively. Results: 
Results from CFA indicated an adequate fit with the data for the two-factor SF-12v2 
model with minor modifications. As per known-groups validity, the SF-12v2 MCS 
domain adequately distinguished adults with autism by severity, with higher MCS 
score observed among adults with low autism severity as compared to those with 
high autism severity. However, contrary results were observed for the PCS domain. 
High internal consistency reliability was observed for the PCS domain (Cronbach’s 
alpha 0.87), MCS domain (Cronbach’s alpha 0.73), and overall instrument (Cronbach’s 
alpha 0.84). There were no floor and ceiling effects. cOnclusiOns: The SF-12v2 had 
good construct validity, and the factor structure fit well with the data. The known-
groups validity of the SF-12v2 warrants further investigation in this population. 
Reliability of the instrument was good, and there were no floor and ceiling effects. 
Overall, SF-12v2 had adequate psychometric properties among adults with autism.
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Objectives: To assess the content validity and patient interpretation of the Self-
Reported Misuse, Abuse and Diversion (SR-MAD) of Prescription (Rx) Opioids instru-
ment. MethOds: A cross-sectional, qualitative study was conducted in patients 
with chronic or acute pain. Patients were recruited from 3 clinical sites based on 
three patient groups (opioid naïve, known opioid abusers, and chronic opioid non-
abusers) to participate in a one-on-one cognitive interview. Patients completed the 
SR-MAD instrument via web-administration and then participated in an in-depth 
discussion following a semi-structured interview guide to assess the patient’s 
understanding of the questionnaire. Descriptive statistics and content analysis were 
performed. Results: Thirty-seven patients were interviewed: 11 opioid naïve; 13 
known abusers; and 13 non-abusers. Mean age was 55 ± 13.5 years (range 26 to 84); 
33 patients (89%) experienced chronic pain, three (8%) experienced acute pain, and 
one (3%) experienced both chronic and acute pain. Overall, most patients (n= 31, 84%) 
demonstrated a comprehensive understanding of the questionnaire’s content and 
reported the SR-MAD was easy to complete via web-administration. The majority of 
patients (n= 28, 76%) reported they were truthful when completing the questionnaire 
and most (n= 22, 59%) said they were comfortable completing the questionnaire 
using a secure internet site. Although some patients (n= 15, 41% [opioid naïve n= 5, 
known abusers n= 7, and non-abusers n= 3]) reported there were questions about 
opioid misuse that were not applicable to them, they all understood what was 
being asked and thought the questions would be relevant if they were abusing pain 
medication. Eight patients (known abusers n= 4, non-abusers n= 1, opioid naïve n= 3) 
reported they were not comfortable answering the SR-MAD honestly in a clinic/doc-
tor’s office. cOnclusiOns: The SR-MAD was developed based on patient input and 
addresses opioid abuse, misuse, and diversion. Additional interviews with aberrant 
opioid abusers are underway to further examine the content validity of the SR-MAD.
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Objectives: The purpose of this study was to determine the predictors of quality of 
life (QOL) among adults with autism. A modified version of Wilson and Cleary’s QOL 
conceptual model was used to study the relationship between autism severity, coping, 
functional independence, social support and QOL in adults with autism. MethOds: 
A cross-sectional, descriptive quantitative design was utilized for this study. An inter-
net-based survey using Qualtrics online software system was administered to adults 
with autism enrolled with the Interactive Autism Network (IAN). Among these adults, 
those who were: 1) aged 18 years and above; and 2) capable of self-reporting with little 
or no proxy help were identified and approached for participation. Structural equation 
modeling (SEM) was used to identify the inter-relationship among study variables 
and to identify the factors influencing QOL among adults with autism. Results: 
The survey sample included 262 adults with autism. Results from the SEM analysis 
revealed the modified Wilson and Cleary’s QOL model tested in the study to have an 
adequate fit (chi-square= 49.75, df= 17; RMSEA= 0.88; CFI= 0.95). Significant correlations 
among coping, functional independence, social support and QOL domains (p< 0.05) 
were observed. Study results depicted autism severity, maladaptive coping, appraisal 
social support and functional independence as significant predictors of physical and 
environment QOL. Autism severity had a significant (p< 0.05) negative impact on 
physical, psychological and environment QOL. Higher degree of social support and 
adaptive coping were found to have a positive influence on QOL. cOnclusiOns: 
Modifiable variables including social support and coping were found to influence QOL 
among adults with autism. Physicians and other health care professionals involved in 
the management of autism among these adults should consider these factors when 
designing treatment intervention strategies.
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what or very much affected their performance at work. In our multivariate logistic 
regression model examining change in employment status, the number of hours/
week of caregiving, use of support services, a PHQ-2 depression score of 4+, caring 
for a spouse, younger age and lower income were statistically significant. In our 
analysis examining change in work performance, the number of hours/week of 
caregiving, use of support services, PHQ-2 score of 4+, providing assistance with 
greater number of ADLs and greater number of IADLs, and younger age were signifi-
cant. cOnclusiOns: Informal caregivers report high levels of change in employ-
ment and performance. Caregiver burden and the presence of depressive symptoms 
were strongly associated with a change in employment status and work perfor-
mance as a result of caregiving. Efforts aimed at identifying high levels of caregiver 
burden and depressive symptoms among caregivers may potentially have an impact 
on employment for some caregivers.
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Objectives: Little is known about the real-world utilization and cost outcomes 
associated with different treatment modalities for opioid dependence. This study 
sought to analyze pre- and post-treatment cost and service utilization data from 
a multi-site, retrospective, naturalistic study of opioid dependent adults in three 
Pennsylvania residential rehabilitation programs. MethOds: De-identified ret-
rospective electronic data on 7,687 patients treated in one of three residential 
treatment centers in Pennsylvania were linked with Medicaid administrative 
data. Duration of Medicaid supported treatment and relative Medicaid costs and 
treatment patterns were compared across 4 different treatment modalities: 1) 
extended-release naltrexone (XR-NTX), 2) agonist (methadone), 3) partial agonist 
(buprenorphine), and 4) drug-free treatment. Costs and utilization patterns in the 
immediate phase after discontinuation were also compared. Results: XR-NTX-
treated (vs. non-medicated) patients were half as likely (odds ratio [OR] 0.47; 95%CI 
0.22-1.00; p< 0.05) to leave against medical advice (AMA), three times more likely 
to complete rehab (OR 3.26; 95% CI 1.70-6.23; p< .01) and twice as likely to initiate 
follow-up treatment within 7-10 days (OR 1.92; 95% CI 1.33-2.77; p< .01). Among the 
4,311 patients for whom Medicaid data were available, costs among XR-NTX treated 
patients were lower than for a non-XR-NTX treated comparison group in the month 
following treatment discontinuation ($1,463 vs. $1,613). cOnclusiOns: Although 
the study is limited due to non-randomization and retrospective administrative 
data, it represents real-world clinical experience and health care spending costs. 
Patients receiving XR-NTX were less likely to leave residential treatment AMA, more 
likely to initiate follow-up treatment, and had lower Medicaid costs in the month 
following treatment discontinuation.
PMH76
a+kiDs: finDings 2-years Post-iMPleMentation of a web-baseD 
registry for antiPsycHotics in cHilDren anD aDolescents
Wegner S.E.1, Moran K.2
1AccessCare, Morrisville, NC, USA, 2North Carolina Community Care Network, Raleigh, NC, USA
Objectives: Children and adolescents with severe behavioral health problems 
are often treated with complex psychoactive medication regimens with unclear 
diagnostic and treatment history, amplified by sporadic and often poorly-coordi-
nated treatment. Recently, the use of antipsychotic medications in children has 
grown substantially among DMA enrollees and now constitutes $44.4 million in 
pharmacy reimbursement costs annually. MethOds: Policy was developed that 
required prescribers to register patients via A+KIDS, a web portal, when prescrib-
ing antipsychotics in patients under 18 years old before the medication could be 
approved for pharmacy reimbursement. Required registration elements included a 
patient’s primary diagnosis, target symptom, initiating prescriber, caregiver support 
of medication use, adverse drug events, and metabolic monitoring deemed best 
practice. A+KIDS registry data, including children age 17 and under data, were used 
to examine the first two years of the registry. Results: A total of 1650 providers 
made 51346 requests for 20434 patients in the first two years of the registry. The 
most commonly requested drug was Risperidone (40.68% of the requests). “Bipolar 
Disorder,” “ADHD,” and “Oppositional Defiant Disorder” were the three most com-
mon diagnoses (33.76%). “Aggression towards others,” “Irritability” and “Tantrums/
temper” were the most common target symptoms (62.12%). Over half (52.48%) of the 
medications were first prescribed by an outpatient psychiatrist. Glucose monitor-
ing increased from 52% to 64% and lipid monitoring from 27% to 46% for children 
on antipsychotics. cOnclusiOns: Most prescribers of antipsychotics in children 
were enthusiastic about participating in the prescribing registry, expressing con-
cern about prescribing in an ill-coordinated environment with high risk of serious 
adverse events and long term side effects. Asking prescribers about glucose and lipid 
values increased monitoring significantly with implementation of the registry. The 
registry has the potential for increasing awareness about the effects and usefulness 
of these medicines by enhancing claims data with clinical data.
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Objectives: Prescription Drug Monitoring Programs (PDMPs) have been enacted 
by several states to combat the abuse and diversion of controlled substances (CS). 
reduced HRQoL, especially physical component score, in elderly dementia patients. 
The study findings suggest the need to evaluate anticholinergic burden, and if pos-
sible, use of these potentially inappropriate agents should be avoided in the vulner-
able dementia patients.
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Objectives: We examined Health-Related Quality of Life (HRQoL) of adoles-
cents and adults with Down syndrome (DS) and test-retest reliability of the 
KIDSCREEN-27. MethOds: We conducted a multi-lingual, non-drug, longitudinal 
study in 8 countries. Sixty-one participants were included (30 males, 31 females). 
Assessments were performed at baseline and week 24. The KIDSCREEN-27 Parent-
Form uses a 5-point Likert scale and comprises five domains: Physical Wellbeing 
(range 5-25), Psychological Wellbeing (range 7-35), Autonomy & Parent Relations 
(range 7-35), Peers & Social Support (range 4-20), and School Environment (range 
4-20). Higher scores indicate improved HRQoL. A clinician global rating of improve-
ment (ranging from 1 ‘very much improved’ to 7 ‘very much worse’) was used to 
assess participant clinical status. Intra-class correlations for participants rated 
as “no change” were calculated to assess test-retest reliability of the KIDSCREEN 
between baseline and week 24. Results: The average age was 14 years and 23 
years in adolescents (N= 34) and adults (N= 27), respectively. The following base-
line KIDSCREEN raw scores were obtained for adolescents and adults respectively: 
Physical Wellbeing 17.4 ± 3.65 and 15.5 ± 2.94; Psychological Wellbeing 28.1 ± 3.65 
and 28.4 ± 4.02; Autonomy and Parent Relations 26.0 ± 4.92 and 28.4 ± 4.16; Peers and 
Social Support 12.1 ± 3.74 and 13.6 ± 4.14; School Environment 15.4 ± 2.41 and 15.6 ± 
2.08. Thirty-five respondents were deemed stable. The KIDSCREEN-27 showed fair to 
good test-retest reliability (range ICC 0.44 to 0.76) with the exception of Autonomy 
and Parent Relations (-0.16) and Psychological Wellbeing (0.19) in adolescents, and 
Physical Wellbeing (0.32) and School Environment (0.30) in adults. cOnclusiOns: 
At baseline both adolescents and adults displayed a reasonable HRQoL as measured 
by the KIDSCREEN-27. Test-retest reliability may have been influenced by the long 
timeframe between the two assessments.
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Objectives: Opioid dependence not only impacts health outcomes and health 
care costs in the US, but also imposes a large economic burden on the workplace. 
Estimated lost workplace productivity accounts for the largest share (~$25.6 billion 
or 45.6%) of total societal costs.41This study evaluated the impact of extended-
release naltrexone (XR-NTX), available as a once-monthly injectable treatment 
option for preventing relapse to opioid dependence, on self-reported substance 
use and employment status, in patients treated in a real-world, naturalistic 
study. MethOds: Analysis of an open-label, single-arm, US multicenter registry of 
adult, opioid dependent outpatients initiating XR-NTX treatment following detoxifi-
cation. Substance use and employment status in the previous 28 days were collected 
via the National Treatment Agency Treatment Outcomes Profile (TOP). Analyses were 
conducted in patients with data available from baseline until at least 6 months of 
XR-NTX treatment. Intra-subject paired hypothesis tests were conducted. Results: 
A total of 112 (26.6%) of 403 enrolled registry patients had over 6 months of on-
treatment follow-up, with 99 (24.6%) completing Month 6 assessments. Abstinence 
rates for opioids (45.5% to 95.0%; p= 0.001), alcohol (64.7% to 78.8%; p= 0.006), and 
stimulants (crack, cocaine and amphetamine) (82.8% to 96.0%; p= 0.002) signifi-
cantly increased from baseline to Month 6. Baseline to Month 6 unemployment 
rates significantly decreased from 53.5% to 37.4% (p= 0.005). Among 53 patients 
unemployed at baseline, the majority (55.3%) reported employment at Month 6, 
with 17.0% indicating working 1-16 days and 28.3% working > 16 days in the prior 
28 days. cOnclusiOns: In this real-world registry, XR-NTX was associated with 
increased rates of opioid abstinence, as demonstrated in previous controlled stud-
ies. While limitations include the uncontrolled design and the sample subset with 
6 months of data, this is the first study to find that patients in XR-NTX treatment 
showed reductions in overall drug use, with concurrent increased employment.
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Objectives: The objective of this study was to identify factors associated with a 
change in work performance (Model #1) and with a change in employment sta-
tus (Model #2) among informal caregivers. We hypothesized caregiver burden and 
caregiver mental health were key potentially modifiable characteristics of these 
two outcomes. MethOds: A representative (U.S.) sample of 705 adult caregivers 
completed an online survey regarding their role as an informal caregiver and its 
impact on their employment. Model II examined 544 of the 705 respondents due 
to missing data. We conducted bivariate analyses and used multivariate logistic 
regression to assess the impact of caregiver burden, caregiver mental and physical 
health, caregiver relationship, and use of caregiving support services on: a change 
in work performance and a change in employment status. Sociodemographic vari-
ables were also examined. Results: 32% (n= 176) of caregivers reported being laid 
off or resigned from their position while 46% (n= 322) reported caregiving some-
